Difference between revisions of "Mesna (Mesnex)"

Revision as of 16:26, 3 December 2017

General information

Class/mechanism: Detoxifying agent to reduce the risk of hemorrhagic cystitis with agents such as Ifosfamide (Ifex). Mesna is rapidly metabolized to mesna disulfide (dimesna), which remains intravascular and is rapidly processed by the kidneys, where it is converted back into mesna. Mesna binds to the urotoxic metabolites of ifosfamide, acrolein and 4-hydroxy-ifosfamide, limiting the risk of hemorrhagic cystitis. It has not been shown to interfere with antitumor efficacy.^[1]^[2]
Route: IV, PO
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Patient drug information

History of changes in FDA indication

12/30/1988: Initial FDA approval

Also known as

Precise Name: Mesna (RXCUI 44)

Synonyms
Anti Uron	MEI AN	Mesa	Mesna-Cell	Mesna Delta Farma	Mesna Filaxis	Mesna GI Kendrick	Mesna Microsules
Mesnex	Mesnil	Mestian	Mistabron	Mistabronco	Mitexan	Mucolene	Neper
Novacarel	Siruta	Uromes	Uromitexan	Uroprot	Varimesna

References

[insert-1] 1.0 ^1.1 ^1.2 Mesna (Mesnex) package insert

[2] Mesna (Mesnex) package insert (locally hosted backup)

[3] Mesna (Mesnex) patient drug information (Chemocare)

[4] Mesna (Mesnex) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 4: / Line 4: @@
 <br>Extravasation: no information
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 ==Patient drug information==